hVIVO plc

("hVIVO", the "Company" or the "Group")

>£5 million CRS contracts signed

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September.

The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS' strong reputation and long-standing relationships in Germany. These pharma partnerships, given their volume and consistency, strengthens the Group's sales pipeline and orderbook for 2026 and beyond. These trials are due to commence this year and H1 2026 with the majority of revenue recognised in 2026.

The trials will take place at the Mannheim and Kiel sites studying drug candidates targeting multiple therapeutic areas including cardiometabolic, dermatology, infectious disease, renal impairment, and cancer. CRS has strong expertise across this range of therapeutic areas, expanding the Group's addressable market. Venn Life Sciences will be supporting these contracts with its Biometry service, demonstrating the cross-selling benefits being realised from the integration of CRS into the Group.

CRS have conducted over 1,800 clinical trials and provides advice to its clients across every aspect of their study, from feasibility and study design to trial management, recruitment, execution, and close-out. These studies span Phase I and Phase II in healthy volunteers and patients, supported by CRS' participant recruitment platform, recently enhanced by hVIVO's Volunteer Management System improving efficiency in recruitment for CRS trials.

Dr Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "Securing over £5 million in new contracts, including two mid-sized pharma clients, underscores our strong reputation and the strategic importance of CRS within the Group. These wins demonstrate the success of our integration strategy and the value we deliver through combined expertise across the hVIVO Group. CRS has seen an increased conversion rate of proposals to contracts year-to-date versus 2024 and with a robust sales pipeline and continued efficiency improvements, CRS remains on track to become earnings accretive in 2026."

Professor Thomas Forst, Chief Medical Officer of hVIVO, said: "At CRS, we are committed to delivering high-quality clinical trial services that accelerate the development of safe and effective medicines for patients worldwide. These new studies span multiple therapeutic areas and showcase the depth of our expertise and the trust our clients place in us. By combining scientific excellence with operational efficiency, we continue to strengthen our position as a leading partner for early-phase clinical research."

For further information please contact:

Notes to Editors

hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.